Potent MCH-1 receptor antagonists from cis-1,4-diaminocyclohexane-derived indane analogs
摘要:
Benzimidazole and indane are the two key fragments in our potent and selective MCH-1 receptor (MCHR1) antagonists. To identify novel linkers connecting the two fragments, we investigated diamino-cycloalkane-derived analogs and discovered highly potent antagonists with cis-1,4-diaminocyclohexane as a unique spacer in this chemical class. Structural overlay suggested that cis-1-substituted-4-aminocyclohexane functions as a bioisostere of 4-substituted-piperidine and that the active conformation adopts a U-shaped orientation. (C) 2013 Elsevier Ltd. All rights reserved.
Provided herein are compounds of the formula (I):
as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of obesity, hyperphagia, anxiety, depression and related disorders and diseases.
Provided herein are compounds of the formula (I):
as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of obesity, hyperphagia, anxiety, depression and related disorders and diseases.
DIAMINOCYCLOHEXANE AND DIAMINOCYCLOPENTANE DERIVATIVES
申请人:F. Hoffmann-La Roche AG
公开号:EP2089368A1
公开(公告)日:2009-08-19
US7652053B2
申请人:——
公开号:US7652053B2
公开(公告)日:2010-01-26
[EN] DIAMINOCYCLOHEXANE AND DIAMINOCYCLOPENTANE DERIVATIVES<br/>[FR] DÉRIVÉS DE DIAMINOCYCLOHEXANE ET DE DIAMINOCYCLOPENTANE
申请人:HOFFMANN LA ROCHE
公开号:WO2008065021A1
公开(公告)日:2008-06-05
[EN] Provided herein are compounds of the formula (I) as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of obesity, hyperphagia, anxiety, depression and related disorders and diseases. [FR] L'invention concerne des composés représentés par la formule (I) ainsi que des sels pharmaceutiquement acceptables de ceux-ci, les substituants étant tels qu'indiqués dans la description. Ces composés, et les compositions pharmaceutiques les contenant, sont utiles pour le traitement de l'obésité, de l'hyperphagie, de l'anxiété, de la dépression et de troubles et maladies apparentés.